NCT04594798View on ClinicalTrials.gov

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
DLBCLLymphoma, B-Cell
Interventions
DRUG

Polatuzumab vedotin

IV 1.8 mg/kg per cycle

DRUG

Rituximab

IV 375 mg/m2 per cycle

DRUG

Cyclophosphamide

IV 400 mg/m2 per cycle

DRUG

Doxorubicin

IV 25 mg/m2 per cycle

DRUG

Prednisone

PO 40 mg/m2 per cycle

Trial Locations (1)

14642

RECRUITING

University of Rochester, Rochester

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Rochester

OTHER